Intra-Cellular Therapies, Inc. (ITCI)
After hours:
- GuruFocus.com
Intra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA Sales
Robust Growth and Positive Clinical Results Propel Forward Momentum
- Zacks
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 48.39% and 2.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024 CAPLYTA total prescriptions increased 39%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance reiterated at $645 - $675 million Announced robust positive Phase 3 results from Study 501 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive
